9 results about "Chloral hydrate" patented technology

The invention discloses a preparation method of chloral hydrate oral liquid, which comprises the following steps: 1) preparation of chloral hydrate microspheres: dissolving chloral hydrate in an organic solvent, and then adding a carrier material into the solution to obtain an oil phase; adding a surfactant into deionized water to form a water phase; slowly dropwise adding the oil phase into the water phase while stirring and performing ultrasonic treatment to obtain an emulsion; continuously stirring the emulsion, removing the organic solvent, gradually solidifying the medicine and the carrier material in the oil phase to form microspheres, washing, separating and drying to obtain chloral hydrate microspheres; 2) preparation of chloral hydrate oral liquid: dissolving sorbitol in water to obtain a sorbitol aqueous solution; and adding the chloral hydrate microspheres into a sorbitol aqueous solution to obtain the chloral hydrate oral liquid. The chloral hydrate oral liquid prepared by the method has relatively high stability, and meanwhile, the acceptability of a patient is improved.

The invention belongs to the field of pharmaceutical analysis, and particularly relates to a method for detecting impurities in a chloral hydrate sample, which comprises the following steps of: performing optimization pretreatment on the chloral hydrate sample, and performing accurate quantitative analysis on trichloromethane impurities in the sample by adopting a gas chromatography direct injection combined temperature programming technology. The method has the characteristics of high specificity, high accuracy and strong durability.

The present application relates to the chemical technology field, specifically to a kind of preparation method of high-purity o-vanillin.The method uses o-methoxyphenylamine as starting material, with chloral hydrate and hydroxylamine hydrochloride is condensed, hydroxylamine oximation reaction, and cyclization reaction is carried out under strong acid condition, and compound 2 is generated;Compound 2 is oxidized under strong base condition, and compound 3 is generated;Compound 3 is esterified with primary alcohol to generate corresponding ester, and then reduction hydrogenation reaction is carried out under the action of strong reducing agent, and compound 4 is generated;Compound 4 is reacted with oxidizing agent in the presence of nitroxyl radical catalyst, and compound 5 is generated;Compound 5 carries out diazotization hydrolysis reaction, and o-vanillin is generated.The method avoids the problem of regioselectivity of traditional formylation reaction through specific reaction sequence, eliminates the generation of isomer impurities from the source, realizes the efficient, environmentally friendly, economic synthesis of high-purity o-vanillin, and provides high-quality raw material guarantee for downstream pharmaceutical.

The chloral hydrate enemator comprises an enema assembly, the enema assembly comprises an anal tube, size scale marks are marked on the anal tube, and a side hole is formed in the side edge of the head of the anal tube; the injector assembly comprises an injection empty cylinder and a piston shaft, the interior of the injection empty cylinder is used for storing chloral hydrate, the head of the piston shaft is provided with a rubber piston embedded with the injection empty cylinder, the piston shaft is sleeved in the injection empty cylinder, and the head of the injection empty cylinder is provided with an injection nipple. A patient is subjected to enema through the enema assembly, the size scale marks on the anal tube ensure that the insertion depth is accurate, a medical worker controls the insertion depth according to the scales, the interior of the injection empty cylinder is used for storing chloral hydrate, the scales of the injection empty cylinder ensure that the input amount of the chloral hydrate is accurate, and the device is easy to operate, is a disposable article and is convenient to use. Medical staff can directly use the device, one device is used and one device is lost, cross infection is avoided, the number of accessories is small, operation steps are simplified, and the enema efficiency of the medical staff is improved.

The present invention discloses a stable chloral hydrate syrup, its preparation method, quality control method and application, belonging to the technical field of pharmaceuticals, and solves the problems in the prior art that chloral hydrate has poor stability, harsh storage conditions, short shelf life, and needs to be diluted during use. A stable chloral hydrate syrup of the present invention comprises chloral hydrate, sucrose and water, wherein the mass-volume concentration of chloral hydrate is 10%, and the pH value of the chloral hydrate syrup is 2.3 - 3.0. The chloral hydrate syrup of the present invention further comprises glycerol. The chloral hydrate syrup of the present invention adopts the specification with a chloral hydrate sugar concentration of 10% used clinically, does not need to be freshly prepared before use, has accurate dosage, is safe and controllable, and has stable properties.

The invention discloses a polygonum cuspidatum extract, the effective components of the polygonum cuspidatum extract are mainly resveratrol and paeoniflorin, and the contents of the resveratrol and the paeoniflorin are respectively 1.25 mg / g and 1.50 mg / g. The invention also discloses a bacteriostatic gynecological lotion. The formula of the bacteriostatic gynecological lotion is as follows by mass: (1) 0.1% of the polygonum cuspidatum extract; (2) lactic acid bacteria: 1 * 10 < 8 > CFU / ml; (3) 0.02% of chloral hydrate; (4) 1% of plant glycerin; and (5) the pH value is 4.2. The novel bacteriostatic gynecological lotion provided by the invention has an excellent bacteriostatic effect, can maintain normal flora in the vagina, and is suitable for adjuvant therapy and daily nursing of various gynecological diseases.

The invention discloses a method for detecting related substances of chloral hydrate and a preparation thereof, which adopts a high performance liquid chromatography, and the chromatographic conditions are as follows: octadecylsilane chemically bonded silica is used as a chromatographic column of a filler, an acid-containing aqueous solution is used as a mobile phase A, acetonitrile is used as a mobile phase B, and gradient elution comprises 90-97% of the mobile phase A in 0-5min; the mobile phase A is 80-90% in 9-12 min; the mobile phase A accounts for 10-30% in 25-35 min; according to the related substance detection method, degradation impurities such as formic acid, acetic acid and trichloroacetic acid and process impurities such as 2, 2, 3, 3-tetrachlorosuccinic acid can be detected at the same time by optimizing the elution gradient, and the detection method is high in sensitivity, accuracy and precision and good in reproducibility.

The invention relates to the field of drug detection and analysis, in particular to a method for detecting degraded impurities such as carboxylic acids and aldehydes of chloral hydrate. According to the detection method, high performance liquid chromatography is adopted, octadecyl silane bonded silica gel is adopted as a filling agent, an ultraviolet detector is adopted, and the detection wavelength is 195 nm + / -2 nm. According to the detection method, effective separation of auxiliary material peaks and related substances can be achieved, peak patterns of all peaks are good, the separation degree between impurity peaks and main peaks and the separation degree between the impurity peaks meet the requirements of pharmacopeia, and specificity is good. The method is suitable for drug registration quality research of chloral hydrate and preparations thereof.

The application discloses a preparation method of a bladder cancer orthotopic tumor-bearing rat model of blood stasis and toxin syndrome, and has the characteristics that 0.3ml / g of chloral hydrate is injected into the abdominal cavity of an SD rat to perform anesthesia, after the anesthesia takes effect, the rat is fixed in a supine position, the perineum of the rat is disinfected with iodophor, a catheter is slowly inserted into the bladder along the posterior wall of the urethral orifice of the rat to suck out urine, 0.2mL of MNU solution is injected into the bladder of the rat, after the injection is completed, the catheter is withdrawn, and the urethral orifice is gently clamped, the injection is repeated once every two weeks, and the injection is performed four times in total, 0.2ml of adrenaline hydrochloride is subcutaneously injected into the nape of the rat, the injection is performed once every two days, and the injection is continuously performed for eight weeks, the self-tumorigenic model of the bladder cancer model of the rat is constructed, compared with tumor-bearing and ectopic transplantation and other bladder cancer models, the model can better reflect the pathological process of the bladder cancer, the model construction simultaneously considers the syndrome characteristics of the blood stasis and toxin syndrome of traditional Chinese medicine, is beneficial to observation of the pathological process of the blood stasis and toxin type bladder cancer model in the later stage, and can be used for observation of curative effects and indexes after intervention of traditional Chinese medicines.